Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses

Professors discuss groundbreaking studies in Psoriatic Arthritis, focusing on bimekizumab's rapid efficacy for pain and fatigue relief. They delve into long-term results from guselkumab, revealing sustained clinical improvements over two years. The importance of personalized treatment strategies is highlighted, especially concerning the impact of background therapies. They also emphasize patient-reported outcomes, demonstrating how insights into patients' experiences can significantly enhance care and treatment approaches.